Pramlintide Combined With Model Predictive Control Algorithm

Inclusion Criteria: * Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least six months (the diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determination are not needed). * Age 21 to 65 years * For females, not currently known to be pregnant * An understanding of the protocol and a willingness to follow it * HbA1c between 7 and 9% * Normal renal function (determined utilizing the comprehensive metabolic panel at screening with the Modification of Diet in Renal Disease (MDRD) formula and defined by estimated Glomerular Filtration Rate (eGFR) of ≥60 ml/min/1.73 m2. * Hematocrit \>36 (females); \>38 (males) Exclusion Criteria: * Known hypersensitivity to SYMLIN or any of its components, including metacresol * Poor compliance with current insulin regimen * Poor compliance with prescribed self-blood glucose monitoring * HbA1c \<7 or \>9% * Severe hypoglycemia resulting in seizure or loss of consciousness in the 2 weeks prior to enrollment * Active infection * Current use of dietary supplements (subjects may be enrolled if they stop taking dietary supplements two weeks prior to admission and for the duration of their participation) * Active gastroparesis * Use of drugs that stimulate gastrointestinal motility (e.g. metoclopramide) * Diabetic ketoacidosis in the past 3 months * Current treatment for a seizure disorder * Cystic fibrosis * Asthma requiring hospitalization or treatment with oral steroids within the past year * Presence of a uncontrolled adrenal disorder * A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples: * Inpatient psychiatric treatment in the past 6 months * Abnormal liver function (Transaminase \>2 times the upper limit of normal) * Heart failure * Coronary artery disease * Arrhythmia * Seizure disorder * Any carcinogenic disease * Creatinine concentration above the upper limit of normal for age and sex * Active coronary artery disease * Uncontrolled thyroid disease * Use or abuse of alcohol * Active kidney dialysis * If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study * Note: adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment * Addison's disease * Current use of a beta blocker medication * Hematocrit \< 36 (female), \<38 (male) * Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study * Allergy to the sensor or to one of its components * Continued use of acetaminophen.